Pranesh Kumar

About

Dr. Pranesh Kumar currently working as an Assistant Professor at the Institute of Pharmaceutical Sciences, University of Lucknow. He completed B. Pharm from PSIT Kanpur and qualified GATE/GPAT. He completed his M. Pharm from BBAU Lucknow (A Central University) and awarded by Double Gold medal. He completed his Ph.D. in Pharmacology from BBAU Lucknow (A Central University) and got DST INSPIRE fellowship (JRF & SRF). He published more than 40 research papers in reputed international journals like Nature, Elsevier, Taylor & Francis and Springer. His research expertise in Anti-Cancer, Nanoformulations, Isolation of natural products, Spectroscopic Analysis, Anti-diabetic, Drug Design and Discovery, In silico Drug Design, In vitro and In vivo pharmacological screening of novel molecules, Pharmacological Screening at molecular levels and NMR based metabolomics.

Employment

• University of Lucknow Assistant Professor
  2022 - Present
• Aryakul College of Pharmacy and Research Assistant Professor
  2021 - 2022
• Shakti College of Pharmacy Balrampur, UP Assist Professor
  2015 - 2016

Education

• Babasaheb Bhimrao Ambedkar University Ph.D. (Pharmacology)
  2016 - 2020
• Babasaheb Bhimrao Ambedkar University M.Pharm (Pharmacology)
  2013 - 2015
• Pranveer Singh Institute of Technology B.Pharm
  2009 - 2013

Projects & Funding

Projects & funding information is unavailable.

Publications (55)

• Therapeutic Evaluation of Kaempferol-loaded Liposomes in Hepatocellular Carcinoma through i-NOS/e-NOS/p53/Caspase-Mediated Apoptotic Pathway
  Journal of Pharmaceutical Innovation 2026 DOI: 10.1007/s12247-026-10776-8
  +Save
• FNDC5/irisin mitigates the cardiotoxic impacts of cancer chemotherapeutics by modulating ROS-dependent and -independent mechanisms
  REDOX BIOLOGY 2025 DOI: 10.1016/J.REDOX.2025.103527
  +Save
• Metabolites involvement in the growth and spread of liver cancer
  LIVER RESEARCH 2025 DOI: 10.1016/J.LIVRES.2025.10.005
  +Save
• FNDC5/irisin mitigates the cardiotoxic impacts of cancer chemotherapeutics by modulating ROS-dependent and -independent mechanisms (vol 80, 103527, 2025)
  REDOX BIOLOGY 2025 DOI: 10.1016/J.REDOX.2025.103734
  +Save
• Mechanistic and metabolic exploration of neohesperidin against lung cancer cell lines through ROS-mediated mitochondrial apoptosis: An in-silico and in-vitro approach
  Toxicology and Applied Pharmacology 2025 DOI: 10.1016/j.taap.2025.117350
  +Save
• Computational Approaches Molecular Docking and MD Simulation Establishes the Potential COVID-19 Main Protease Inhibitors from Natural Products
  Current Chinese Science 2024 DOI: 10.2174/0122102981273400231220112631
  +Save
• A Comprehensive Review on Exosome: Recent Progress and Outlook
  Pharmaceutical Nanotechnology 2024 DOI: 10.2174/2211738511666230523114311
  +Save
• Appraisal of folate functionalized bosutinib cubosomes against hepatic cancer cells: In-vitro , In-silico , and in-vivo pharmacokinetic study
  INTERNATIONAL JOURNAL OF PHARMACEUTICS 2024 DOI: 10.1016/J.IJPHARM.2024.123975
  +Save
• Novel bioinspired dinuclear Cu(II) 'paddle wheel' acetate complex: Catalytic and in vitro biological activity studies
  JOURNAL OF MOLECULAR STRUCTURE 2024 DOI: 10.1016/J.MOLSTRUC.2023.137263
  +Save
• Preclinical evaluation of dalbergin loaded PLGA-galactose-modified nanoparticles against hepatocellular carcinoma via inhibition of the AKT/ NF-κB signaling pathway
  INTERNATIONAL IMMUNOPHARMACOLOGY 2024 DOI: 10.1016/J.INTIMP.2024.112813
  +Save